FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220937170> ?p ?o ?g. }

• W4220937170 abstract "Abstract Apoptosis is a highly regulated cellular process. Aberration in apoptosis is a common characteristic of various disorders. Therefore, proteins involved in apoptosis are prime targets in multiple therapies. Bcl‐x L is an antiapoptotic protein. Compared to other antiapoptotic proteins, the expression of Bcl‐x L is common in solid tumors and, to an extent, in some leukemias and lymphomas. The overexpression of Bcl‐x L is also linked to survival and chemoresistance in cancer and senescent cells. Therefore, Bcl‐x L is a promising anticancer and senolytic target. Various nanomolar range Bcl‐x L inhibitors have been developed. ABT‐263 was successfully identified as a Bcl‐x L /Bcl‐2 dual inhibitor. But it failed in the clinical trial (phase‐II) because of its on‐target platelet toxicity, which also implies an essential role of Bcl‐x L protein in the survival of human platelets. Classical Bcl‐x L inhibitor designs utilize occupancy‐driven pharmacology with typical shortcomings (such as dose‐dependent off‐target and on‐target platelet toxicities). Hence, event‐driven pharmacology‐based approaches, such as pr oteolysis ta rgeting c himeras (PROTACs) and SNIPERs ( s pecific n on‐genetic I AP‐based p rotein er asers) have been developed. The development of Bcl‐x L based PROTACs was expected, as 600 E3‐ligases are available in humans, while some (such as cereblon (CRBN), von Hippel‐Lindau (VHL)) are relatively less expressed in platelets. Therefore, E3 ligase ligand‐based Bcl‐x L PROTACs (CRBN: XZ424, XZ739; VHL: DT2216, PZ703b, 753b) showed a significant improvement in platelet therapeutic index than their parent molecules ( ABT‐263 : DT2216, PZ703b, 753b, XZ739, PZ15227; A1155463 : XZ424). Other than their distinctive pharmacology, PROTACs are molecularly large, which limits their cell permeability and plays a role in improving their cell selectivity. We also discuss prodrug‐based approaches, such as antibody‐drug conjugates ( ABBV‐155 ), phosphate prodrugs ( APG‐1252 ), dendrimer conjugate ( AZD0466 ), and glycosylated conjugates ( Nav‐Gal ). Studies of in‐vitro , in‐vivo , structure‐activity relationships, biophysical characterization, and status of preclinical/clinical inhibitors derived from these strategies are also discussed in the review." @default.
• W4220937170 created "2022-04-03" @default.
• W4220937170 creator A5076308838 @default.
• W4220937170 creator A5081472090 @default.
• W4220937170 date "2022-03-19" @default.
• W4220937170 modified "2023-10-14" @default.
• W4220937170 title "Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐x _L Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches" @default.
• W4220937170 cites W1964181289 @default.
• W4220937170 cites W1980727670 @default.
• W4220937170 cites W1983509869 @default.
• W4220937170 cites W2010178708 @default.
• W4220937170 cites W2018221677 @default.
• W4220937170 cites W2031130939 @default.
• W4220937170 cites W2032469948 @default.
• W4220937170 cites W2041600945 @default.
• W4220937170 cites W2047859169 @default.
• W4220937170 cites W2049126730 @default.
• W4220937170 cites W2057068774 @default.
• W4220937170 cites W2062132637 @default.
• W4220937170 cites W2063110724 @default.
• W4220937170 cites W2065571058 @default.
• W4220937170 cites W2069432530 @default.
• W4220937170 cites W2071535939 @default.
• W4220937170 cites W2073239885 @default.
• W4220937170 cites W2076721909 @default.
• W4220937170 cites W2085419794 @default.
• W4220937170 cites W2090958270 @default.
• W4220937170 cites W2090967845 @default.
• W4220937170 cites W2102503292 @default.
• W4220937170 cites W2110525250 @default.
• W4220937170 cites W2113703332 @default.
• W4220937170 cites W2125446149 @default.
• W4220937170 cites W2139900059 @default.
• W4220937170 cites W2143257102 @default.
• W4220937170 cites W2158467294 @default.
• W4220937170 cites W2164786703 @default.
• W4220937170 cites W2168632005 @default.
• W4220937170 cites W2168990146 @default.
• W4220937170 cites W2172242534 @default.
• W4220937170 cites W2299508065 @default.
• W4220937170 cites W2304433628 @default.
• W4220937170 cites W2326615470 @default.
• W4220937170 cites W2328925456 @default.
• W4220937170 cites W2622149303 @default.
• W4220937170 cites W2742198482 @default.
• W4220937170 cites W2758733287 @default.
• W4220937170 cites W2791182171 @default.
• W4220937170 cites W2900854047 @default.
• W4220937170 cites W2902781827 @default.
• W4220937170 cites W2944504593 @default.
• W4220937170 cites W2989708739 @default.
• W4220937170 cites W2990669650 @default.
• W4220937170 cites W2997600890 @default.
• W4220937170 cites W2998840182 @default.
• W4220937170 cites W3006981712 @default.
• W4220937170 cites W3008322752 @default.
• W4220937170 cites W3014006805 @default.
• W4220937170 cites W3017437536 @default.
• W4220937170 cites W3019334729 @default.
• W4220937170 cites W3065218857 @default.
• W4220937170 cites W3093395956 @default.
• W4220937170 cites W3095961126 @default.
• W4220937170 cites W3106920023 @default.
• W4220937170 cites W3111404439 @default.
• W4220937170 cites W3123438528 @default.
• W4220937170 cites W3163057307 @default.
• W4220937170 cites W3170396526 @default.
• W4220937170 cites W3182488106 @default.
• W4220937170 cites W3187443993 @default.
• W4220937170 cites W3201370051 @default.
• W4220937170 cites W3206911536 @default.
• W4220937170 cites W3214609263 @default.
• W4220937170 cites W3215130076 @default.
• W4220937170 cites W4200357687 @default.
• W4220937170 cites W4220937170 @default.
• W4220937170 cites W4225753704 @default.
• W4220937170 doi "https://doi.org/10.1002/cbic.202100689" @default.
• W4220937170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35263486" @default.
• W4220937170 hasPublicationYear "2022" @default.
• W4220937170 type Work @default.
• W4220937170 citedByCount "19" @default.
• W4220937170 countsByYear W42209371702022 @default.
• W4220937170 countsByYear W42209371702023 @default.
• W4220937170 crossrefType "journal-article" @default.
• W4220937170 hasAuthorship W4220937170A5076308838 @default.
• W4220937170 hasAuthorship W4220937170A5081472090 @default.
• W4220937170 hasBestOaLocation W42209371701 @default.
• W4220937170 hasConcept C104317684 @default.
• W4220937170 hasConcept C108215921 @default.
• W4220937170 hasConcept C134459356 @default.
• W4220937170 hasConcept C185592680 @default.
• W4220937170 hasConcept C190283241 @default.
• W4220937170 hasConcept C203014093 @default.
• W4220937170 hasConcept C25602115 @default.
• W4220937170 hasConcept C2778540781 @default.
• W4220937170 hasConcept C502942594 @default.
• W4220937170 hasConcept C55493867 @default.
• W4220937170 hasConcept C86803240 @default.
• W4220937170 hasConcept C89560881 @default.
• W4220937170 hasConcept C98274493 @default.

• next